Bahija Jallal (Source: MedImmune)

Wood­ford who? TCR-fo­cused Im­muno­core sol­diers on with $130M+ B round

Im­muno­core — once a dar­ling of the now-dis­graced Neil Wood­ford — is shak­ing off its past by rais­ing more than $130 mil­lion in a Se­ries B haul.

The Ox­ford­shire, UK-based com­pa­ny, which launched in 2015 to ad­vance its T cell re­cep­tor (TCR) tech­nol­o­gy with a mam­moth $320 mil­lion round, was soon glo­ri­fied with a val­u­a­tion of near­ly $1 bil­lion (£800m). That uni­corn sta­tus proved to be its Achilles heel, trig­ger­ing an ex­o­dus of top man­age­ment in re­cent years as po­ten­tial in­vestors balked at the old val­u­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.